Press Releases April 28, 2026 06:30 AM

BOSS Zhipin's Ongoing Share Repurchases Reach Nearly RMB1.07 Billion in 2026

KANZHUN LIMITED Continues Aggressive Share Buyback Program, Spending Nearly RMB1.07 Billion in 2026

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED (traded as BZ on Nasdaq) has continued its share repurchase program with a recent buyback of approximately RMB27.3 million for 588,046 shares. The company has consistently repurchased shares for 26 trading days and has spent nearly RMB1.07 billion on buybacks so far in 2026, signaling strong commitment to enhancing shareholder value.

BOSS Zhipin's Ongoing Share Repurchases Reach Nearly RMB1.07 Billion in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has repurchased shares for 26 consecutive trading days in 2026.
  • The company has spent nearly RMB1.07 billion on share repurchases year-to-date.
  • The latest buyback involved approximately RMB27.3 million for 588,046 ordinary shares.

BEIJING, April 28, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB27.3 million to repurchase 588,046 ordinary shares on April 27. With this latest transaction, the Company has made repurchases for the past 26 consecutive trading days, deploying nearly RMB1.07 billion toward share repurchases year-to-date in 2026. This effort underscores the Company's ongoing commitment to delivering value to shareholders.


Risks

  • Continued large share buybacks may strain company cash reserves or impact liquidity.
  • Market or regulatory changes could affect the ability to continue share repurchases.
  • Share repurchase programs may not lead to sustained stock price appreciation if company fundamentals deteriorate.

More from Press Releases

Willis appoints Trevor Madden as Head of Captive and Insurance Management Solutions, Asia Pacific Sep 6, 2026 Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund Sep 6, 2026 Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026